Cancer's Hidden Weakness: Synthetic Lethality! PARP Inhibitors and Beyond
In this article
Synthetic Lethality in Cancer Therapy
Explore the field's dynamics interactively (2015–2025)
What Is Synthetic Lethality?
An approach that aims to selectively eliminate cancer cells by exploiting their genetic weaknesses through simultaneous targeting of complementary pathways.
Scenario A: Loss of Gene A
Gene A is defective in the cancer cell; the cell survives through pathway B. Outcome: survival
Scenario B: Inhibition of Gene B
Gene B is inhibited by a drug; pathway A compensates. Outcome: survival
A + B: Synthetic lethality
Targeting B in a cell lacking A shuts down both pathways. Outcome: cancer cell death
Key Milestones (2015–2025)
Follow key dates in the journey from the clinical success of PARP inhibitors to the discovery of new targets such as WRN.
2015: The Rise of PARP Inhibitors
Olaparib ushered in a new era with broad approval in BRCA-mutated ovarian cancer.
2017: New Targets Through CRISPR
CRISPR screens accelerated genome-wide discovery of synthetic-lethal partners.
2020: Expanding Indications
PARP inhibitors expanded into prostate and pancreatic cancer.
2023: WRN Helicase
WRN targeting showed strong biological effects in MSI-H tumors.
2024: Artificial Intelligence Models
Algorithms predicting potential SL pairs from big data became more widespread.
Explore Synthetic Lethality Interactions
Use the filters; the chart and information panel update dynamically.
Overview
Select an interaction to display its mechanism and associated cancers here.
Mechanism
-
Associated Cancers
-
Clinical Trial Landscape
Distribution by drug class × phase.
Challenges and Future Outlook
Resistance mechanisms, biomarker development, and rational combinations are the main research priorities.
💥 Drug Resistance Mechanisms Reactivation, alternative survival pathways, and early resistance signatures Priority: High
Clinical Tips
- Rebiopsy / liquid biopsy for secondary-mutation screening
- After PARPi: BRCA reversion mutation testing
- HRR restoration & drug efflux monitoring
Research Directions
- Sequential/combination PARPi + ATRi strategies
- In WRN targeting: synthetic escape signatures
- Biomarkers predicting early resistance
🧬 Biomarker Discovery Genomics, MSI/MTAP, and multi-omics integration for appropriate patient selection Priority: High
Practical Panel
- HRR gene panel + MSI + TMB
- MTAP deletion (FISH/NGS, copy number)
- MMR deficiency signature for WRN dependency
Near-Term Outlook
- Multi-omics score (genomics + expression + phosphoproteomics)
- ctDNA-based early response/resistance signatures
- AI-based likelihood score for SL pairs
➕ Combination Therapies Rational pairings of PARPi/WRNi/PRMT5i with ICIs and chemotherapy Priority: Medium
Example Strategies
- PARPi + ATRi (amplifying replication stress)
- WRNi + ICI (neoantigen load hypothesis)
- PRMT5i + chemotherapy (epigenetic sensitivity)
Points for Attention
- Overlapping hematological toxicities
- Dose intensity / sequential scheduling
- Early endpoint: adaptive design using ctDNA decline
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.